MCID: PTT008
MIFTS: 48

Pituitary Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Pituitary Carcinoma

MalaCards integrated aliases for Pituitary Carcinoma:

Name: Pituitary Carcinoma 12 52 58 6 15 71
Pituitary Cancer 52 17
Malignant Neoplasm of Pituitary Gland 71
Carcinoma of the Pituitary Gland 12

Characteristics:

Orphanet epidemiological data:

58
pituitary carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:4916
MeSH 43 D010911
NCIt 49 C4536
SNOMED-CT 67 128665000 254955001
ICD10 32 C75.1
ICD10 via Orphanet 33 C75.1
UMLS via Orphanet 72 C0346300
Orphanet 58 ORPHA300385
UMLS 71 C0346300 C0496842

Summaries for Pituitary Carcinoma

MalaCards based summary : Pituitary Carcinoma, also known as pituitary cancer, is related to prolactin producing pituitary tumor and hormone producing pituitary cancer. An important gene associated with Pituitary Carcinoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Aldosterone synthesis and secretion and DNA Damage. The drugs Lapatinib and Parathyroid hormone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and spinal cord, and related phenotypes are pituitary carcinoma and headache

Related Diseases for Pituitary Carcinoma

Diseases related to Pituitary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 32.0 PRL POMC MGMT
2 hormone producing pituitary cancer 30.7 SSTR2 SST PRL POMC MEN1 GPR101
3 chromophobe adenoma 30.4 PRL POMC
4 amenorrhea 30.3 PRL POMC CRH
5 diabetes insipidus 30.2 PRL POMC CRH
6 hypopituitarism 29.9 PRL POMC GHRH CRH
7 hyperprolactinemia 29.7 SST PRL POMC GNAS GHRH
8 hyperthyroidism 29.6 SST PRL POMC GNAS
9 paraganglioma 29.6 SST MEN1 CHGA
10 lynch syndrome 29.3 TP53 PMS2 MGMT BRCA2
11 hypothyroidism 29.3 SST PRL POMC GNAS GHRH
12 neuroendocrine tumor 29.2 SSTR2 SST POMC MEN1 GHRH CHGA
13 nelson syndrome 29.1 SSTR2 SST PRL POMC MGMT CRH
14 pituitary tumors 28.8 SST PTTG1 PRL POMC MEN1 GNAS
15 meningioma, familial 28.6 TP53 SSTR2 SST PRL POMC MGMT
16 pituitary apoplexy 28.3 SST PRL POMC MEN1 AIP
17 pheochromocytoma 28.2 SST PRL POMC MEN1 MEG3 CRH
18 conn's syndrome 28.2 SST PRL POMC MEN1 GNAS GHRH
19 acth-secreting pituitary adenoma 27.4 SSTR2 SST PRL POMC MIR93 MEN1
20 pituitary adenoma, prolactin-secreting 27.2 SSTR2 SST PTTG1 PRL POMC MIR93
21 multiple endocrine neoplasia, type i 27.2 SST PRL POMC MEN1 GPR101 GNAS
22 acromegaly 27.2 SSTR2 SST PRL POMC MEN1 GPR101
23 pituitary adenoma 26.6 SSTR2 SST PTTG1 PRL POMC MEN1
24 functioning pituitary adenoma 26.5 SSTR2 SST PRL POMC MIR93 MEN1
25 adenoma 26.0 TP53 SSTR2 SST PTTG1 PRL POMC
26 bronchial adenomas/carcinoids childhood 10.5 SST POMC
27 chiasmal syndrome 10.5 SST POMC
28 acth-independent macronodular adrenal hyperplasia 1 10.5 POMC GNAS
29 appendix carcinoid tumor 10.5 PMS2 CHGA
30 breast juvenile papillomatosis 10.5 GNAS BRCA2
31 duodenal benign neoplasm 10.5 SST CHGA
32 ampulla of vater neoplasm 10.5 SST CHGA
33 type c thymoma 10.5 SSTR2 SST
34 carotid body cancer 10.4 SST CHGA
35 paternal uniparental disomy 10.4 MEG3 GNAS
36 gastric hemangioma 10.4 SST CHGA
37 appendix lymphoma 10.4 SST CHGA
38 diffuse midline glioma, h3 k27m-mutant 10.4 MGMT BRCA2
39 lung oat cell carcinoma 10.4 POMC CHGA
40 adenohypophysitis 10.4 PRL POMC
41 glucagonoma 10.4 SST CHGA
42 appendix adenocarcinoma 10.4 GNAS CHGA
43 fibrous dysplasia/mccune-albright syndrome 10.4 PRL GNAS
44 tuberculum sellae meningioma 10.4 PRL POMC
45 sella turcica neoplasm 10.4 PRL POMC
46 cerebral lymphoma 10.4 SSTR2 SST
47 gastroenteropancreatic neuroendocrine neoplasm 10.4 MGMT CHGA
48 fasting hypoglycemia 10.4 POMC CRH
49 colon neuroendocrine neoplasm 10.4 POMC CHGA
50 osseous heteroplasia, progressive 10.4 POMC GNAS BRCA2

Graphical network of the top 20 diseases related to Pituitary Carcinoma:



Diseases related to Pituitary Carcinoma

Symptoms & Phenotypes for Pituitary Carcinoma

Human phenotypes related to Pituitary Carcinoma:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pituitary carcinoma 58 31 obligate (100%) Obligate (100%) HP:0011763
2 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
3 pituitary prolactin cell adenoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0006767
4 malignant neoplasm of the central nervous system 58 31 hallmark (90%) Very frequent (99-80%) HP:0100836
5 increased circulating acth level 58 31 hallmark (90%) Very frequent (99-80%) HP:0003154
6 increased circulating prolactin concentration 58 31 hallmark (90%) Very frequent (99-80%) HP:0000870
7 pituitary corticotropic cell adenoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0008291
8 hemianopia 58 31 frequent (33%) Frequent (79-30%) HP:0012377
9 hypopituitarism 58 31 frequent (33%) Frequent (79-30%) HP:0040075
10 progressive visual field defects 58 31 frequent (33%) Frequent (79-30%) HP:0007987
11 enlarged pituitary gland 58 31 frequent (33%) Frequent (79-30%) HP:0012505
12 reduced visual acuity 31 frequent (33%) HP:0007663
13 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
14 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
15 growth hormone excess 58 31 occasional (7.5%) Occasional (29-5%) HP:0000845
16 pituitary growth hormone cell adenoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0011760
17 spinal cord lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0100561
18 diabetes insipidus 58 31 very rare (1%) Very rare (<4-1%) HP:0000873
19 pituitary gonadotropic cell adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0011759
20 pituitary thyrotropic cell adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0011762
21 mildly reduced visual acuity 58 Frequent (79-30%)
22 hyperpituitarism 58 Occasional (29-5%)
23 abnormality of central motor function 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 MEN1 TP53

MGI Mouse Phenotypes related to Pituitary Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 AIP BRCA2 CHGA CRH GHRH GNAS
2 endocrine/exocrine gland MP:0005379 10.25 AIP BRCA2 CHGA CRH GHRH GNAS
3 growth/size/body region MP:0005378 10.14 AIP BRCA2 CHGA CRH GHRH GNAS
4 immune system MP:0005387 10.06 BRCA2 CRH GHRH GNAS MEN1 PMS2
5 liver/biliary system MP:0005370 9.91 AIP CRH GHRH GNAS MEN1 PMS2
6 neoplasm MP:0002006 9.81 AIP BRCA2 GNAS MEN1 MGMT PMS2
7 nervous system MP:0003631 9.77 BRCA2 CHGA CRH GHRH GNAS MEN1
8 no phenotypic analysis MP:0003012 9.23 CHGA CRH GNAS MGMT POMC PTTG1

Drugs & Therapeutics for Pituitary Carcinoma

Drugs for Pituitary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
2
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
3 Protein Kinase Inhibitors Phase 2
4 Radiopharmaceuticals Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
2 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
3 Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) Completed NCT01903967
4 PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France) Recruiting NCT02854228

Search NIH Clinical Center for Pituitary Carcinoma

Genetic Tests for Pituitary Carcinoma

Anatomical Context for Pituitary Carcinoma

MalaCards organs/tissues related to Pituitary Carcinoma:

40
Pituitary, Thyroid, Spinal Cord, Liver, Lymph Node, Bone, Lung

Publications for Pituitary Carcinoma

Articles related to Pituitary Carcinoma:

(show top 50) (show all 271)
# Title Authors PMID Year
1
Pituitary surgery's epidemiology using a national inpatient database in Japan. 61
32125502 2020
2
Metastatic Pituitary Carcinoma Causing Cord Compression. 61
32289505 2020
3
Pituitary Adenomas with Changing Phenotype: A Systematic Review. 61
32289831 2020
4
A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database. 61
32206537 2020
5
Results and predictors of outcome of endoscopic endonasal surgery in Cushing's disease: 20-year experience of an Italian referral Pituitary Center. 61
32215861 2020
6
Aggressive prolactinomas: how to manage? 61
31617128 2020
7
Pituitary carcinoma: Two case reports and review of literature. 61
32133278 2020
8
Pituitary tumours - a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre. 61
32154573 2020
9
[The effectiveness of risk stratification systems in diagnosis of nodular thyroid disorders]. 61
32202723 2019
10
Multimodal therapy in aggressive pituitary tumors. 61
31740190 2019
11
Treatment and long-term outcomes in pituitary carcinoma: a cohort study. 61
31349217 2019
12
Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors. 61
31929698 2019
13
Extraordinary case presentations in pediatric pituitary adenoma: report of 6 cases. 61
31604323 2019
14
Nelson-Salassa Syndrome Progressing to Pituitary Carcinoma: A Case Report and Review of the Literature. 61
31700708 2019
15
[Pituitary carcinoma: is it too late?] 61
31497872 2019
16
Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. 61
31267325 2019
17
An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. 61
30706322 2019
18
Matrine inhibits the proliferation of pituitary tumor cells by decreasing Foxo3a phosphorylation and promoting Foxo3a nuclear localization. 61
30988763 2019
19
Pituitary carcinomas: review of the current literature and report of atypical case. 61
30836020 2019
20
Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma. 61
30447452 2019
21
Xenoestrogen interference with nongenomic signaling actions of physiological estrogens in endocrine cancer cells. 61
30012504 2019
22
Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with pituitary adenoma. 61
31933748 2019
23
Downregulation of glucose‑6‑phosphate dehydrogenase by microRNA‑1 inhibits the growth of pituitary tumor cells. 61
30272333 2018
24
Pathological Findings in the Pituitary Glands of Dogs and Cats. 61
29929454 2018
25
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. 61
30085142 2018
26
Neuro-Ophthalmic Manifestations of Pituitary Carcinoma. 61
29315125 2018
27
Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. 61
29404894 2018
28
Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? 61
29318507 2018
29
Combined modalities of surgery, radiotherapy, radiosurgery and chemotherapy for invasive pituitary carcinoma. 61
29525560 2018
30
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). 61
29299820 2018
31
MicroRNA‑16/VEGFR2/p38/NF‑κB signaling pathway regulates cell growth of human pituitary neoplasms. 61
29399695 2018
32
MicroRNAs and Target Genes in Pituitary Adenomas. 61
29351706 2018
33
Prolactin Secreting Pituitary Carcinoma with Extracranial Spread Presenting with Pathological Fracture of Femur. 61
29456370 2018
34
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. 61
29046323 2018
35
Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review. 61
30460199 2018
36
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. 61
28586933 2018
37
Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. 61
29928263 2018
38
Pituitary Carcinoma in a Patient with an SDHB Mutation. 61
28284009 2017
39
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide. 61
29256415 2017
40
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma. 61
29137963 2017
41
Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort. 61
28938458 2017
42
Metastatic prostate adenocarcinoma to intradural foramen magnum. 61
29181146 2017
43
Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. 61
28667593 2017
44
Advancements in the study of miRNA regulation during the cell cycle in human pituitary adenomas. 61
28577032 2017
45
Meningeal dissemination of a pituitary carcinoma to the cauda equina in a dog. 61
28761190 2017
46
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. 61
28291643 2017
47
Cytomorphology of metastatic pituitary carcinoma to the bone. 61
28267302 2017
48
Seeding of a Pituitary Adenoma or Atypical Pituitary Carcinoma? 61
28589060 2017
49
Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease. 61
28420444 2017
50
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review. 61
28109841 2017

Variations for Pituitary Carcinoma

ClinVar genetic disease variations for Pituitary Carcinoma:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PMS2 NM_000535.7(PMS2):c.137G>T (p.Ser46Ile)SNV Likely pathogenic 9245 rs121434629 7:6045549-6045549 7:6005918-6005918
2 BRCA2 NM_000059.4(BRCA2):c.4850G>A (p.Ser1617Asn)SNV Conflicting interpretations of pathogenicity 37928 rs397507341 13:32913342-32913342 13:32339205-32339205

Expression for Pituitary Carcinoma

Search GEO for disease gene expression data for Pituitary Carcinoma.

Pathways for Pituitary Carcinoma

GO Terms for Pituitary Carcinoma

Cellular components related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.8 POMC CHGA BRCA2

Biological processes related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.95 SSTR2 SST POMC GPR101 GNAS GHRH
2 negative regulation of cell proliferation GO:0008285 9.83 TP53 SSTR2 SST MIR93 MEN1
3 cell-cell signaling GO:0007267 9.76 SST POMC GPR101 GHRH
4 DNA repair GO:0006281 9.72 PTTG1 PMS2 MGMT MEN1 BRCA2
5 female pregnancy GO:0007565 9.67 PRL GNAS CRH
6 positive regulation of cAMP-mediated signaling GO:0043950 9.52 GNAS CRH
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.51 TP53 BRCA2
8 negative regulation of telomerase activity GO:0051974 9.48 TP53 MEN1
9 chromosome organization GO:0051276 9.43 TP53 PTTG1 BRCA2
10 cellular response to DNA damage stimulus GO:0006974 9.43 TP53 PTTG1 PMS2 MGMT MEN1 BRCA2
11 hormone-mediated apoptotic signaling pathway GO:0008628 9.37 SST CRH
12 response to gamma radiation GO:0010332 9.33 TP53 MEN1 BRCA2
13 response to drug GO:0042493 9.1 TP53 SST PMS2 MGMT GNAS CRH

Molecular functions related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 SST PRL POMC GHRH CRH
2 corticotropin-releasing hormone receptor 1 binding GO:0051430 8.96 GNAS CRH

Sources for Pituitary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....